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Abstract
Background: We investigated whether the ‘obesity paradox’ in heart failure (HF) is influ-
enced by common confounders, and assessed if body surface area (BSA) may correlate more 
closely than body mass index (BMI) with prognosis.
Methods: We studied 630 systolic HF patients at their initial visit to the HF clinic. Body size 
was measured by BMI and BSA. The association between body indices and mortality was as-
sessed by Cox proportional-hazard analyses.
Results: There were 248 deaths during mean follow-up of 39 months. A progressive inverse 
association of BMI and BSA tertiles (T1–T3) with mortality risk was observed (for BSA: T3, 
reference, T2, hazard ratio [HR] 1.41, 95% confidence interval [CI] 1.01–1.95, p = 0.04 and 
T1, HR = 1.78, 95% CI 1.29–2.45, p < 0.001; for BMI: T3, reference, T2, HR = 1.29, 95% CI 
0.92–1.79, p = 0.13 and T1, HR = 1.66, 95% CI 1.21–2.27, p = 0.002). The obesity paradox 
was attenuated after multivariate adjustment, and did not persist after adjustment for age alone 
(for BMI: T3, reference, T2, HR = 1.13, 95% CI 0.81–1.58, p = 0.47; T1, HR = 1.30, 95% 
CI 0.94–1.80, p = 0.12; for BSA: T3, reference, T2, HR = 0.96, 95% CI 0.68–1.35, p = 0.82;  
T1, HR = 1.15, 95% CI 0.82–1.63, p = 0.42).
Conclusions: BSA provides prognostic information similar to BMI in systolic HF. However, 
the obesity paradox of both BMI and BSA in HF may be confounded by the younger age of the 
obese patients. (Cardiol J 2015; 22, 4: 375–381)
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Introduction
Obesity adversely impacts cardiovascular (CV) 
risk factors as well as left ventricular structure 
and function. Accordingly, it is an established risk 
factor for the development of CV diseases includ-
ing heart failure (HF) [1–3]. However, numerous 
studies have demonstrated over the years that in 
patients with existing HF, obesity is unexpectedly 
associated with better survival [4–9]. This no-
tion that overweight and obese individuals have 
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survival advantage compared with leaner subjects 
was reported in addition to HF in several other 
chronic CV disease conditions and is named the 
‘obesity paradox’ [10, 11].
Several potential mechanisms trying to explain 
the obesity paradox in HF are suggested in the 
literature [12]. These include among others, the ef-
fects of cardiac cachexia, catabolic state and muscle 
wasting in lean HF subjects, in contrast to greater 
metabolic reserve and increased muscle mass and 
strength in overweight and obese HF individuals. 
In addition, it is implicated that confounding factors 
which are unmeasured or not fully adjusted for, 
may account for the inverse relationship between 
obesity and mortality seen in HF cohorts [13]. 
These factors include variance in the prevalence 
of comorbidities in the obese vs. lean HF subjects, 
such as higher blood pressures allowing for more 
cardiac medications, lower incidence of smoking, 
and younger age at presentation of the disease al-
lowing earlier medical treatment.
Nevertheless, the influence of obesity on over-
all mortality in chronic HF remains unclear and it 
is still debated if there is an intrinsic association 
between obesity and mortality in HF subjects, 
or whether the obesity paradox is confounded by 
other uncontrolled factors contributing to its exist-
ence [14, 15].
Furthermore, most studies demonstrating the 
obesity paradox have used body mass index (BMI), 
and less commonly measures of central obesity, as 
an index of overweight and obesity in HF [16]. Nev-
ertheless, BMI may not be a good way to correct 
weight for height. Accordingly, potential methods 
for describing body size such as body surface area 
(BSA), commonly used for indexing physiologic 
parameters associated with HF, may correlate more 
closely with prognosis in HF.
The objective of the current study was to 
investigate the prognostic significance of BSA, in 
comparison with BMI, as markers of body habitus in 
a cohort of chronic systolic HF subjects evaluated 
at their initial visit to the HF clinic. In addition, 
we aimed to determine whether the association 
between obesity and mortality is influenced by 
common confounders.
Methods
Study population 
The study population included 637 consecu-
tive chronic systolic HF patients, defined as left 
ventricular ejection fraction (LVEF) < 40%. Seven 
patients had BMI < 18.5 kg/m2 and were excluded 
from data analysis due to a small group size of un-
derweight patients. All subjects had documented 
BMI and BSA measurements carried out at their 
initial visit to a tertiary outpatient HF clinic. BSA 
was calculated according to the Mosteller formula 
[weight (kg) × height (cm) /3600]1/2 [17]. Mosteller 
formula is recommended as an accurate measure 
to estimate BSA, and is commonly used due to 
its simplicity and applicability in both clinical 
and laboratory medicine [18]. Patients were cat-
egorized according to tertiles of BSA [T1 ≤ 1.79; 
1.79 < T2 ≤ 1.99; T3 > 1.99] and BMI (kg/m2) 
[T1 ≤ 25.5; 25.5 < T2 ≤ 30.4; T3 > 30.4].
Baseline characteristics and co-morbidities 
were recorded in all patients, including age, gen-
der, presence of hypertension, diabetes mellitus, 
coronary artery disease, paroxysmal/permanent 
atrial fibrillation, New York Heart Association 
(NYHA) grade, laboratory values of hemoglobin 
and creatinine, and treatment with beta-blockers, 
angiotensin converting enzyme blockers or an-
giotensin receptor blockers (ACEI/ARBs). QRS 
segment width (ms) was recorded from electrocar-
diogram tracings; LVEF and left atrial dimension 
were assessed by 2-dimensional echocardiographic 
studies. Data concerning all-cause mortality during 
the follow-up period were gathered from patients’ 
electronic files and computerized records of health 
maintenance organizations.
The study was approved by the Lady Davis 
Carmel Medical Center Institutional Review Board.
Data analysis
Continuous data are presented as means 
± standard deviation, and categorical variables as 
numbers or percentages. The χ2 test was used to 
compare categorical variables. Kruskal-Wallis test 
and one-way analysis of variance (ANOVA) test 
were used to compare continuous variables where 
appropriate. Survival curves were plotted by the 
Kaplan-Meier method using the log-rank test for 
assessing the significance of the differences in 
survival between tertiles in each comparison.
In order to assess the prognostic value of 
BMI and BSA, the patients were divided into 
tertiles based on their BMI or BSA, and a mul-
tivariate analysis was performed using the Cox 
proportional–hazards regression analysis with the 
tertile index serving as the explanatory variable. 
Hazard ratios (HR) for death were calculated ac-
cording to tertiles of both BMI and BSA, with 95% 
confidence intervals (CI). Adjustment was made 
for gender and other risk factors and baseline 
characteristics by adding them as covariates to 
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the multivariate model. Cut-off for inclusion into 
the multivariate model was a univariate p < 0.10. 
The substantial effect of age on the association 
between obesity and mortality was examined in 
a separate model.
The results were considered statistically sig-
nificant when the p-value was < 0.05. The SPSS 
statistical software version 20.0 was used to per-
form all statistical analyses.
Results
There were 630 consecutive patients (80% 
male) with systolic HF included in the study. Mean 
age was 65 ± 13 years. The mean LVEF of the 
study population was 26 ± 7% and 53% had NYHA 
functional class III/IV at their initial index visit to 
the HF clinic.
Mean BMI level was 28.5 ± 5.2 kg/m2 (median 
27.6) and mean BSA level was 1.90 ± 0.22 m2 
(median 1.88). Baseline clinical characteristics, 
according to BSA and BMI tertiles are presented 
in Table 1. Higher tertiles of BSA and BMI were 
both associated with younger age, higher rates 
of diabetes, left atrial enlargement and elevated 
hemoglobin levels. In addition, upper teritle of 
BMI, but not BSA, was associated with increased 
incidence of hypertension and a small but statis-
tically significant increase in LVEF. Despite the 
widespread use of beta-blockers in the entire study 
cohort, a variance was noted between subgroups, 
showing a tendency towards increased use of beta-
blockers in subjects with higher indices of body 
habitus (Table 1).
During a mean follow-up period of 39 ± 26 
months (median 35), 248 (39%) patients died. 
Mortality during the follow-up period was most 
prevalent in subjects in the low tertile of BSA and 
BMI (47% and 48%, respectively), less prevalent 
in the mid tertile (41% and 37%) and lowest in the 
high tertile subjects (31% and 32%, p = 0.002). 
Absolute mortality rates were not significantly 
different between moderately obese (BMI 30–35 
kg/m2) and severely obese (BMI > 35 kg/m2) 
patients (49/139, 35% vs. 24/84, 29%; p = 0.38). 
Mortality was not’s Figures 1 and 2 show Kaplan-
Meier survival curves according to tertiles of both 
BMI and BSA. Long-term mortality was inversely 
and progressively associated with body habitus, 
illustrating the obesity paradox (log-rank test 
p < 0.001).
Hazard ratios for all-cause mortality are pre-
sented in Table 2 for each tertile of BSA and BMI. 
Compared to the highest tertile of BSA (T3: refer-
ence group), subjects in the lower BSA tertiles had 
significantly increased risk for mortality in an in-
clining pattern (T2: HR = 1.41, 95% CI 1.01–1.95, 
p = 0.04 and T1: HR = 1.78, 95% CI 1.29–2.45, 
p < 0.001). After multivariate adjustment including 
hypertension, history of myocardial infarction, 
LVEF, permanent/paroxysmal atrial fibrillation, left 
atrial dimension, QRS segment width, hemoglobin 
and creatinine levels, NYHA grade, beta-blockers 
and ACEI/ARBs treatment, the inverse associa-
tion between BSA and mortality was weakened 
(Table 2), and did not persist after adding age to the 
multivariate model. Moreover, even after adjust-
ment for age alone the inverse association between 
BSA and mortality disappeared (T3: reference; 
T2: HR = 0.96, 95% CI 0.68–1.35, p = 0.82; T1: 
HR = 1.15, 95% CI 0.82–1.63, p = 0.42). A similar 
pattern of relationship was seen between BMI and 
mortality risk (Table 2). In addition, when BSA 
and BMI were analyzed as continuous variables, 
paradoxical association with all-cause mortality 
was seen, but did not persist after adjustment for 
age (data not shown).
After dividing the study population to sub-
groups according to tertiles of age, no signifi-
cant differences in all-cause mortality were seen 
between BSA tertiles, in any of the age groups 
(Fig. 3).
Discussion
In the current analysis, both BMI and BSA, 
a common measure of body size used for indexing 
physiologic parameters (mainly hemodynamic), 
were similarly inversely associated with mortality 
and provided prognostic information in systolic HF 
patients. The significant paradoxical association 
between both measures reflecting body habitus and 
mortality was eliminated after adjustment for age 
alone, but not after adjustment for other covariates 
including comorbidities, laboratory blood tests and 
drug therapies. Accordingly, the obesity paradox in 
HF may be significantly confounded by the younger 
age of the obese patients.
The obesity paradox in HF has been consist-
ently demonstrated in multiple observational 
studies including meta-analysis and has been 
observed especially with BMI [4–9]. However, 
BMI is not a direct measure of obesity and is 
not an accurate way to correct weight for height. 
BSA correlates more closely to physiologic pa-
rameters than body weight. It is commonly used 
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in medicine, in research and clinical practice, as 
a biometric unit to adjust size, mass and volume, 
in individuals with HF at different body sizes 
[18, 19]. BSA was also shown to be an outcome 
predictor. A very small BSA was found to be an 
independent predictor of worse mortality after 
coronary artery bypass surgery [20]. In another 
study, adult candidates for heart transplantation 
with lower BSA, including most female patients, 
had worse prognosis [21]. In the present study, 
increased body size was associated with better 
survival of patients with chronic systolic HF. BSA 
was a good predictor of survival,  at least as BMI, 
and even after multifactorial adjustment including 
gender. These findings are in accordance with the 
results of a study by Futter et al. [22], reporting 
that BSA was a strong predictor of mortality in 
HF, better than other measures of body habitus 
and irrespective of height correction. The authors 
concluded that the greater the overall bulk of the 
body, the better the survival, and that meeting 
the increased metabolic demand of chronic HF 
Table 1. Patient characteristics according to tertiles of body mass index (BMI) and body surface area (BSA).
Variable All subjects 
(n = 630)
BMI BSA
T1 T2 T3 P T1 T2 T3 P
Gender (male) 505  
(80%)
174  
(82%)
173  
(82%)
158  
(77%)
0.32 138  
(66%)
168  
(80%)
199  
(95%)
< 0.001
Age [years] 65 ± 13 67 ± 15 66 ± 12 62 ± 12 0.001 69 ± 14 67 ± 12 59 ± 12 < 0.001
Height [cm] 1.67 ± 0.09 1.67 ± 0.08 1.66 ± 0.09 1.66 ± 0.09 0.68 1.60 ±  
± 0.08
1.67 ±  
± 0.07
1.72 ±  
± 0.07
< 0.001
Weight [kg] 79.1 ± 16.3 65 ± 8 77 ± 10 95 ± 13 < 0.001 63 ± 6 77 ± 5 97 ± 11 < 0.001
Hypertension 375  
(59%)
105  
(49%)
125  
(59%)
145  
(70%)
< 0.001 121  
(58%)
128  
(61%)
126  
(60%)
0.66
Diabetes  
mellitus
281  
(44%)
72  
(34%)
95  
(45%)
114  
(55%)
< 0.001 76  
(36%)
100  
(47%)
105  
(50%)
0.012
Myocardial 
infarction
384  
(61%)
123  
(58%)
139  
(66%)
122  
(59%)
0.19 121  
(58%)
142 (67%) 121  
(58%)
0.07
Atrial  
fibrillation
195  
(31%)
66  
(31%)
63  
(30%)
66  
(32%)
0.89 60  
(29%)
74  
(35%)
61  
(29%)
0.28
LVEF [%] 25.8 ± 7.3 24.7 ± 7.1 25.5 ± 7.2 27.1 ± 7.4 0.003 25.4 ±  
± 7.4
26.2 ±  
± 7.4
25.7 ±  
± 7.1
0.58
Left atrium 
[cm]
4.5 ± 0.6 4.4 ± 0.6 4.5 ± 0.5 4.6 ± 0.6 0.03 4.4 ± 0.6 4.5 ± 0.6 4.6 ± 0.6 < 0.001
QRS width 
[ms]
129 ± 36 132 ± 39 128 ± 36 126 ± 33 0.21 129 ± 36 132 ± 40 126 ± 31 0.19
Creatinine [mg/
dL]
1.37 ± 0.72 1.40 ± 0.71 1.38 ± 0.75 1.33 ± 0.71 0.61 1.37 ±  
± 0.72
1.41 ±  
± 0.78
1.33 ±  
± 0.66
0.48
Hemoglobin 
[mg/dL]
12.7 ± 1.7 12.3 ± 1.7 12.8 ± 1.7 12.9 ± 1.7 0.01 12.3 ±  
± 1.6
12.6 ±  
± 1.7
13.1 ±  
± 1.7
0.01
ACEI or ARBs 555  
(88%)
182  
(85%)
188  
(89%)
185  
(89%)
0.33 182  
(87%)
182  
(86%)
191  
(91%)
0.28
Beta-blockers 589  
(93%)
191  
(90%)
203  
(96%)
195  
(94%)
0.037 188  
(90%)
200  
(95%)
201  
(96%)
0.037
NYHA grade 2.6 ± 0.8 2.6 ± 0.9 2.6 ± 0.8 2.6 ± 0.8 0.88 2.6 ± 0.8 2.7 ± 0.8 2.5 ± 0.8 0.19
All-cause  
mortality
248  
(39%)
103  
(48%)
79  
(37%)
66  
(32%)
0.002 98  
(47%)
86  
(41%)
64  
(31%)
0.002
ACEI/ARBs — angiotensin converting enzyme blockers or angiotensin receptor blockers; LVEF — left ventricular ejection fraction; NYHA — 
New York Heart Association
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is likely to be more readily sustained with an 
increased body reserve.
The concept of the obesity paradox in HF is 
controversial, and different studies present con-
flicting results. It is debated whether obesity itself 
may be protective in HF due to factors such as less 
cachexia and inflammatory activation, or whether 
BMI is confounded by other residual factors im-
pacting mortality [23–26]. Studies reporting the 
obesity paradox reveal substantial differences in 
demographic and clinical characteristics of obese 
Figure 1. Survival according to tertiles of body mass 
index (BMI); Kaplan-Meier estimates of survival in pa-
tients with systolic heart failure, according to tertiles 
of BMI (T1–T3). Mean BMI level was 28.5 ± 5.2 kg/m2 
(T1, 23.3 ± 17; T2, 27.8 ± 1.4; T3, 34.6 ± 3.6); log-rank 
p < 0.001.
Figure 2. Survival according to tertiles of body surface 
area (BSA); Kaplan-Meier estimates of survival in patients 
with systolic heart failure, according to tertiles of BSA 
(T1–T3). Mean BSA level was 1.90 ± 0.22 m2 (T1, 1.67 ± 
± 0.09; T2, 1.88 ± 0.06; T3, 2.15 ± 0.13); log-rank 
p < 0.001.
Table 2. Hazard ratios (HR) for mortality risk according to tertiles of body mass index (BMI) and body 
surface area (BSA).
Vari-
able
Ter-
tile
Unadjusted HR Multivariate*  
adjusted HR
Multivariate* + age 
adjusted HR
Age only  
adjusted HR
BSA  
tertiles
T3 1 (reference) 1 (reference) 1 (reference) 1 (reference)
T2 1.41 (1.01–1.95),  
p = 0.04
1.21 (0.86–1.70),  
p = 0.27
0.94(0.66–1.32),  
p = 0.71
0.96 (0.68–1.35),  
p = 0.82
T1 1.78 (1.29–2.45),  
p < 0.001
1.69 (1.21–2.35), 
p=0.002
1.06 (0.74–1.50),  
p = 0.76
1.15 (0.82–1.63),  
p = 0.42
BMI  
tertiles
T3 1 (reference) 1 (reference) 1 (reference) 1 (reference)
T2 1.29 (0.92–1.79),  
p = 0.13
1.18 (0.84–1.66),  
p = 0.33
1.02 (0.73–1.44),  
p = 0.89
1.13 (081–1.58),  
p = 0.47
T1 1.66 (1.21–2.27),  
p = 0.002
1.51 (1.10–2.08),  
p= 0.012
1.11 (0.79–1.55),  
p = 0.56
1.30 (0.94–1.80),  
p = 0.12
*Multivariate Cox regression analysis. Adjusted for gender, hypertension, history of myocardial infarction, left ventricular ejection fraction, 
permanent/paroxysmal atrial fibrillation, left atrial dimension, QRS width, hemoglobin and creatinine level, NYHA grade, beta blockers and 
ACEI/ARBs treatment.
vs. non-obese HF patients [13]. Not infrequently 
obese HF individuals are younger, have higher 
systolic blood pressure, better renal function, 
higher LVEF, better nutritional status, and less 
anemia. Therefore, baseline characteristics favor-
ing patients with higher BMI or BSA may be the 
foundation to their better survival.
In the current study, age was the most sig-
nificant confounder, apparently abolishing the 
obesity paradox seen in systolic HF. Additional 
study investigating the association between obesity 
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obesity is largely explained by the younger age of 
the obese patients, suggesting that there may be 
no intrinsic association between obesity and mor-
tality [27]. In a recent manuscript reviewing the 
obesity paradox in HF, Guglin et al. [13] reported 
a significant difference in age of obese and non-
obese HF patients. In 17 out of 19 studies reporting 
obesity paradox, higher BMI values were found in 
younger HF patients [13]. The authors suggested 
that younger age, which is certainly associated with 
longevity, is associated with many variables which 
not all could simply be accounted for. Therefore, 
customary statistical manipulations aimed at re-
moving the age difference may be limited, leading 
to lack of uniformity in study results.
Limitations of the study
Our study has several limitations. Under-
weight patients were not included in the study 
due to small sample size, and thus the impact of 
cardiac cachexia may not have been truly accounted 
for. BSA has different formulas, some of which 
are complex to calculate and might have impacted 
differently on study results. Lower BSA in female 
patients can also be caused by a group effect be-
cause of their smaller body size. However, in the 
current study, the obesity paradox was not affected 
by adjustment to gender, and the study population 
was predominantly male.
We did not have data on other factors that 
could have also effect on survival in systolic HF, 
such as smoking status and the use of implantable 
cardioverter-defibrillators. Finally, the study was 
conducted in a single center and included predomi-
nantly advanced systolic HF patients. Therefore, 
study results may not be generalized to other 
cohorts of HF population.
Conclusions
In conclusion, BSA provided prognostic in-
formation at least as good as BMI in systolic HF, 
showing an inverse association with all-cause 
mortality. However, the obesity paradox observed 
was eliminated after adjustment for age, suggest-
ing lack of intrinsic association between body size 
indices and mortality in systolic HF. Conducting 
prospective and long-term interventional studies 
may result in better understanding of the obesity 
paradox. Moreover, the utility of BSA as a useful 
prognostic indicator in HF should be further inves-
tigated in future research.
Conflict of interest: None declared
Figure 3. Survival according to body surface area (BSA) 
tertiles (T1–T3), in three age groups; Kaplan-Meier esti-
mates of survival in patients with systolic heart failure, 
in three age groups (age tertiles: age ≤ 60 years (A); 
60 < age ≤ 73 years (B); age  > 73 years (C), according 
to tertiles of BSA (T1–T3); log-rank p = non-significant 
in all subgroups.
and outcomes in post-acute myocardial infarction 
patients with systolic HF, concluded similarly that 
the paradoxical unadjusted survival associated with 
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